VALPROATE        SUPPORTING DATA 
Supporting data
Supported by GSK.
(c) 2004 Excerpta Medica
All rights reserved.
Disclaimer
print this page
 Valproate and PCOS in bipolar women
Authors: Joffee H, et al.
Title: Polycystic ovarian syndrome (PCOS) is associated with valproate use in bipolar women.
Reference: APA 2004 New Research Presentation.
Purpose: To determine whether valproate exposure predisposes bipolar women to PCOS.
Study design: Retrospective observational sub-study from the STEP study.
Follow up: At least 3 months.
Patients: 229 patients taking a mood stabilizer were evaluated for treatment-emergent PCOS (86 divalproex versus 143 non-divalproex).
Treatment: Divalproex or other mood stabilizer.
Results: 10.5% of patients receiving valproate developed PCOS after initiation of therapy compared with 1.4% of patients receiving other mood stabilizers. Treatment-emergent PCOS developed rapidly with valproate treatment (median of 3 months) and was associated with obesity and insulin resistance.  
American Psychiatric Association
polycystic ovarian syndrome
polycystic ovarian syndrome
polycystic ovarian syndrome
polycystic ovarian syndrome
polycystic ovarian syndrome
polycystic ovarian syndrome


 
 


 
home help sitemap acronyms help sitemap home